Chronic lymphocytic leukaemia genomics and the precision medicine era

Br J Haematol. 2017 Sep;178(6):852-870. doi: 10.1111/bjh.14719. Epub 2017 Apr 25.

Abstract

Massive genomic analyses have underscored the diversity of chronic lymphocytic leukaemia (CLL) between patients. Genetic heterogeneity of tumour clones within a patient may fuel tumour evolution. Several recurrently deregulated intra-cellular pathways are candidates for targeted therapies that are very promising and are dramatically changing clinical patients' perspectives. In this review we present an overview of the genetic and epigenetic features of CLL and their clinical and biological implications.

Keywords: chronic lymphocytic leukaemia; mutations; targeted therapy; tumour evolution.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytogenetics / methods
  • DNA Copy Number Variations / genetics
  • Genetic Predisposition to Disease
  • Genomics / methods
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Molecular Targeted Therapy / methods
  • Mutation
  • Precision Medicine / methods*
  • Receptor, Notch1 / genetics
  • Signal Transduction / genetics

Substances

  • NOTCH1 protein, human
  • Receptor, Notch1